Christopher Lee, MD; Alvaro Martinez, MD; Daniel Kim, MD, MBA; Steven E. Finkelstein, MD; and Dwight E. Heron, MD, MBA, FACRO, FACR, discuss how genomic and genetic research is revolutionizing our understanding of prostate cancer risk, progression, personalized treatment strategies, and potential targeted interventions by identifying specific genetic markers, inherited mutations, and molecular pathways that influence disease development and patient outcomes. Featured Video

Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events Featured Video

Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer
Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new treatment for patients with platinum-resistant ovarian cancer.

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data for IMNN-001 in advanced ovarian cancer.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

  Featured Video

  Featured Video